TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01443780

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Selenium and ubiquinon (Q10) combined
Description: A combination of 200 mg/day of coenzyme Q10 (Bio-Quinon 100 mg B.I.D, Pharma Nord, Vejle, Denmark) and 200 µg/day of organic selenium (SelenoPrecise 200 µg, Pharma Nord), or placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium and ubiquinon (Q10) combined
Description: A combination of 200 mg/day of coenzyme Q10 (Bio-Quinon 100 mg B.I.D, Pharma Nord, Vejle, Denmark) and 200 µg/day of organic selenium (SelenoPrecise 200 µg, Pharma Nord), or placebo
Study: NCT02218918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ground walk training
Description: 3 times a week and 6 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Treadmill Walk training
Description: 3 times a week and 6 weeks
Study: NCT02684721

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 8-week home-based exercise programme
Description: 8-week home-based exercise programme is assigned to patients in exercise group following discharge. This includes 3 follow-up telephone calls by physiotherapist.
Study: NCT02287987

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clamp Robotic partial nephrectomy
Description: Renal artery clamping during partial nephrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clampless Robotic partial nephrectomy
Description: Robotic partial nephrectomy without renal artery clamping
Study: NCT03129074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varlitinib
Description: everyday

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: from Day 1 to Day 14 followed by 7-day of rest period, every 21 days.
Study: NCT03671057

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HospiAvontuur
Description: To be included in the study children should play the game at least one time together with one parent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: current practice in Jessa
Study: NCT01822808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydralazine
Description: Hydralazine and placebo will be supplied as 25mg identical tablets and given at a dosage of 75mg/day up to week 4, thereafter 150mg/day up to week 24.
Study: NCT00545129

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Placebo for tanezumab
Description: Single IV infusion of placebo for tanezumab on Day 1. Maintained on baseline opioid regimen.
Study: NCT01822808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide Dinitrate
Description: Isosorbide dinitrate and placebo will be supplied as 10mg identical tablets and given at a dosage of 30mg/day up to week 4, thereafter 60mg/day up to week 24.
Study: NCT03452566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate gel
Description: 3+3 phase 1 design as described above. After the maximum tolerated dose is defined, the phase 2 segment of the study will take place. Simon's Phase 2 study design tool was used, reinforced by Jung's admissible study designs for phase 2 clinical trials. Considering the margin of error of 0.05 and study power of 80%, and estimating the probability of placebo partial response of 15% and partial response to ingenol mebutate in 45%, the optimized number of patients to be recruited is 19. Six patients will be seen in the first stage of this segment of the study, and if only one patient or none has a partial response, the study will be promptly discontinued. Otherwise, the second and final stage of segment of the study will include an additional thirteen patients who will be treated.
Study: NCT04417829

Intervention type: DEVICE
Intervention: Biological prosthesis in the aortic valve
Description: Transcatheter aortic valve implantation of bioprosthesis in patients with severe symptomatic aortic stenosis (clinically indicated)
Study: NCT03873155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy
Description: Mindfulness based cognitive group therapy (MBCT) is a structured eight-week programme (although an extra introductory week will be added in the current study) that combines mindfulness-based exercises with cognitive therapy.
Study: NCT03900390

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cross-preconditioning
Description: After the establishment of the cardiopulmonary bypass, the ascending aorta of the CICP group will be crossclamped 2 minutes, separated by a 3-minute rest interval, and repeated successively on 2 occasions.
Study: NCT03493360

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual feedback
Description: Participants will be asked to perform 10 repetitions of low back flexion, extension and lateral side-flexions while looking at their back in a mirror for visual feedback.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No visual feedback
Description: Participants will be asked to perform 10 repetitions of low back flexion, extension and lateral side-flexions while looking at a mirror that is covered and no visual feedback is provided.
Study: NCT03817372

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior-posterior electrode position
Description: Escalating energy shocks (100 J, 150 J, 200 J, 360 J) using anterior-posterior electrode position
Study: NCT02557477

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3/6 fatty acids
Description: Three Omega 3/6 capsules twice daily
Study: NCT04873011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinine Hydrochloride
Description: After a stabilization period of 20 minutes and 10 minutes after the first blood collection, 10 mL of the quinine hydrochloride solution will be infused into the stomach in a randomized, double-blinded fashion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After a stabilization period of 20 minutes and 10 minutes after the first blood collection, 10 mL of water will be infused into the stomach in a randomized, double-blinded fashion
Study: NCT01884740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIACI of Erbitux and Bevacizumab
Description: Subjects will receive a single intra-arterial dose of Cetuximab (200 mg/m\^2) and Bevacizumab (15 mg/kg) via Superselective Intraarterial Cerebral Infusion (SIACI).
Study: NCT04148391

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Matching placebo capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NYX-458
Description: NYX-458 is a small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
Study: NCT01264120

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Psychology Intervention
Description: The health psychology intervention will involve a bariatric rehabilitation service (BRS) which will involve those allocated to the intervention receiving usual care plus three 50 minute sessions with a health psychologist pre-operatively (1 week before surgery), perioperatively (before they are discharged from hospital) and at 3 month follow up.
Study: NCT03817372

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior-lateral electrode position
Description: Escalating energy shocks (100 J, 150 J, 200 J, 360 J) using anterior-lateral electrode position
Study: NCT01821495

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CIK

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic and Cytokine-induced Killer Cells
Description: Concurrent of radiotherapy and chemotherapy plus 3 cycles of Dendritic and Cytokine-induced Killer Cells(DC-CIK) treatment
Study: NCT00110942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic AMG 108
Description: 300 mg SC AMG 108 Q4W for 3 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic AMG 108
Description: 300 mg SC AMG 108 Q4W for 3 doses

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC placebo injection Q4W for 3 doses

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC placebo injection Q4W for 3 doses
Study: NCT01163071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-011
Description: ABI-011
Study: NCT03843476

Intervention type: DEVICE
Intervention: Patient Specific Rod
Description: Posterior spinal fusion rod
Study: NCT00624520

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Stress Management (CBSM)
Description: 10 week program of weekly CBSM therapy group sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education
Description: 10 week program of Patient Education group sessions, involving presentations of educational materials relating to heart disease.
Study: NCT01925209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYM338/bimagrumab
Description: BYM338, a 150 mg/mL concentrate for solution for i.v. infusion, was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYM338/bimagrumab
Description: BYM338, a 150 mg/mL concentrate for solution for i.v. infusion, was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYM338/bimagrumab
Description: BYM338, a 150 mg/mL concentrate for solution for i.v. infusion, was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to BYM338 was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
Study: NCT00424970

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: acetazolamide
Study: NCT01316393

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: XER2020
Description: mucoprotective product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: XER2020
Description: mucoprotective product

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: XER2020
Description: mucoprotective product
Study: NCT03337256

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: GI bleeding score
Description: Risk factor Score component value Age (years) 15-29 -2 30-44 -1.5 45-59 0 60-74 1.5~* 75 2.5 Haemoglobin(g/L)~* 10.0 0 \<9.9 2 Systolic blood pressure (mmHg)~* 110 0 90-109 1.5 \<90 2.5 Pulse (beats per min) \<100 0~* 100 1.5 Creatinine (mmol/L) \<200 0~* 200 3.5 Number of blood transfusion 0 0~  1 1.5~* 2 2 Presenting symptom Melaena -1.5 Drug treatment Acid blcoking drug 1.5 anticoagulant 3 Endoscopy findings Clean-based ulcer -2 SRH or blood in stomach 4 Varices 5
Study: NCT03932552

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: aerobic exercise program during 2 + 12 weeks, highly monitored and tailored to individual physical capacity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nutritional therapy
Description: individualised nutritional intervention
Study: NCT01423539

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bendamustine
Description: Intravenous repeating dose\\n

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine
Description: Intravenous repeating dose\\n

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: navitoclax
Description: Oral repeating dose\\n

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: Intravenous repeating dose\\n

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Intravenous repeating dose\\n
Study: NCT06201052

Intervention type: OTHER
Intervention: Exercise test
Description: Beep Test for measuring aerobic power

Intervention type: OTHER
Intervention: Exercise test
Description: Beep Test for measuring aerobic power
Study: NCT03014856

Intervention type: OTHER
Intervention: Blood sampling
Description: Determine the metabolic phenotype of blood plasma by proton-NMR spectroscopy

Intervention type: OTHER
Intervention: Blood sampling
Description: Determine the metabolic phenotype of blood plasma by proton-NMR spectroscopy
Study: NCT00715975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: halobetasol
Description: The patients will be treated with halobetasol once a day for 15 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clobetasol
Description: The patients will be treated with clobetasol once a day for 15 days.
Study: NCT02024516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 50 gr concentrated pomegranate juice
Study: NCT02557477

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three placebo capsules twice daily
Study: NCT01181986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide SC
Description: Exenatide 5-10 ug sc BID/10 days
Study: NCT03696992

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tandem colonoscopy
Description: Tandem colonoscopy with different image modalities

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tandem colonoscopy
Description: Tandem colonoscopy with different image modalities

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tandem colonoscopy
Description: Tandem colonoscopy with different image modalities
Study: NCT06345456

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: End-tidal capnography
Description: The value of end-tidal capnography
Study: NCT01700192

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-8237 tablets
Description: MK-8237 12 DU rapidly dissolving tablets administered sublingually q.d.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: Placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue Medication: Self-Injectable Epinephrine
Description: Self-injectable epinephrine (preferred dose of 0.30 mg) administered intramuscularly as needed for rescue medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue Medication: Self-Injectable Epinephrine
Description: Self-injectable epinephrine (preferred dose of 0.30 mg) administered intramuscularly as needed for rescue medication.
Study: NCT01181986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide IV
Description: 50 ng/min intravenously for 45 minutes on 2 out of 3 study visits separated by 5-10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo SC
Description: Placebo sc BID/10days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin-9
Description: Primed (6,000 pM/kg), continuous (600 pM/kg) intravenous infusion for 75 minutes on 1 out of 3 study visits.
Study: NCT01700192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue Medication: Loratadine tablets
Description: Loratadine tablet 10 mg administered orally as needed for rescue medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue Medication: Loratadine tablets
Description: Loratadine tablet 10 mg administered orally as needed for rescue medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue Medication: Olopatadine ophthalmic drops
Description: Olopatadine hydrochloride ophthalmic drops 0.1% administered as needed for rescue medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue Medication: Olopatadine ophthalmic drops
Description: Olopatadine hydrochloride ophthalmic drops 0.1% administered as needed for rescue medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue Medication: Mometasone furoate nasal spray
Description: Mometasone furoate monohydrate nasal spray 50 mcg administered intranasally as needed for rescue medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue Medication: Mometasone furoate nasal spray
Description: Mometasone furoate monohydrate nasal spray 50 mcg administered intranasally as needed for rescue medication.
Study: NCT01181986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo IV
Description: Intravenous infusion for 45 minutes on 1 out of 3 visits
Study: NCT03498274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitting System
Description: End users will drive the screening and fitting flow; however, a trained professional is intended to assist them and help with explanations and the actual fitting of the hearing aids on the person. For a first time user the physical act of placing the hearing aid in/on the ear may create confusion. Therefore, the software is designed for an assistant to guide the user through the process and help with specific parts of the fitting or any questions in general.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Fitting System
Description: The trained professional will fit the hearing aids with the traditional software that is currently used on the market. They will not involve the patient except to play demonstration tones.
Study: NCT01656902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOVOCART® 3D plus
Description: Two-Step intervention: 1) cartilage cells are collected from the patient during arthroscopy 2) collected cartilage cells are cultivated in a sterile environment, seeded in an organic matrix scaffold and implanted into the defect location (knee, femur)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: single-step treatment: defect location (knee, femur) is debrided, then bone plate is drilled mechanically to allow cells from the bone marrow to move to the defect location and to develop a scar tissue
Study: NCT00123643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glyburide
Study: NCT01963481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study: NCT01900093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar Gel
Description: 80 units of subcutaneous Acthar Gel therapy daily
Study: NCT02816957

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nigella sativ
Description: nigella sativa powder (2 gm/day) for 3 consecutive months.
Study: NCT02841410

Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance Imaging
Study: NCT04211246

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Titration of fraction of inspired oxygen (FiO2) guided by SpO2
Description: Titration of fraction of inspired oxygen (FiO2) guided by SpO2

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Titration of fraction of inspired oxygen (FiO2) guided by ORI and SpO2
Description: Titration of fraction of inspired oxygen (FiO2) guided by ORI and SpO2
Study: NCT02103153

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picosure Laser System
Study: NCT00381576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Intervention group: 12 weeks of resistance training for the lower extremity. Control group: No intervention - 12 weeks of normal daily living
Study: NCT04064125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMX-101
Study: NCT02101164

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: denosumab
Description: Treatment Group A - 120 mg SC dose every 4 weeks at Day 1 and week 5 Treatment Group B - 120 mg SC dose every 4 weeks at Week 9 and Week 13

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: denosumab
Description: Treatment Group A - 120 mg SC dose every 4 weeks at Day 1 and week 5 Treatment Group B - 120 mg SC dose every 4 weeks at Week 9 and Week 13
Study: NCT04091256

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single arm clinical study
Description: Participants will be treated with desensitizing toothpaste containing zinc-carbonate hydroxyapatite nanocrystals (Zn-CHA) for 8 weeks.
Study: NCT04185909

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renuvion Dermal System
Description: The Renuvion® Dermal System consists of an electrosurgical generator unit, a handpiece with detachable standoffs, and a supply of helium gas. Radio Frequency (RF) energy is delivered to the handpiece by the electrosurgical generator unit and used to energize an electrode. When helium gas is passed over the energized electrode, a helium plasma is generated which allows for conduction of the RF energy from the electrode to the subject in the form of a precise helium plasma beam.
Study: NCT00763321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-712
Description: ABT-712 extended-release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-712
Description: ABT-712 extended-release tablet
Study: NCT02101164

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pamidronate
Description: Treatment Group A - 90 mg IV dose every 4 weeks at Week 9 and Week 13 Treatment Group B - 90 mg IV dose every 4 weeks at Day 1 and Week 5
Study: NCT00763321

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT03964233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 907828
Description: Film-coated tablets
Study: NCT03996915

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pdt Photodynamic Therapy
Description: device irradiation with low intensity laser (wave length = 660 nm) 9 J (Joules) per point(6 points) and radiant 90 seconds PS will be applied in sufficient quantity to cover the middle third and back of the tongue and wait for 5 minutes.six points with the distances of 1 cm between them will be irradiated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tongue scrapper
Description: Tongue scrapping will be performed by the same operator in all patients. Posterior -anterior movements will be performed with the scrapper over the lingual dorsum. in order to promote the mechanical removal of tongue coating
Study: NCT00022087

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium salts
Description: 1000 mg PO per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium salts
Description: 1000 mg PO per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: 400 IU PO per day
Study: NCT00553722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: Administer Eplerenone, 25 mg,orally twice daily for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administer a placebo tablet orally twice daily for 4 weeks.
Study: NCT01346995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental knee pain
Description: Injection of 1 ml hypertonic saline (5.8%) into the infrapatellar fat pad

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-painful control injections
Description: Injection of isotonic saline into the infrapatellar fat pad